European Monitoring
Background: Atopic eczema (also known as atopic dermatitis, or simply eczema) was traditionally considered to remit in most children by adolescence. However, increasing genetic and epidemiologic evidence suggests that it is an episodic, inflammatory disorder that can occur throughout life (1) . Atopic eczema affects between 10% and 25% of children in industrialized countries, but relatively little is known about physician-diagnosed adult disease (2) .
Objective: To estimate the age-specific prevalence of active atopic eczema across the lifespan in a large primary care population.
Methods and Findings:
We analyzed data between 1994 and 2013 from The Health Improvement Network. This U.K. cohort is known to be accurate; complete; and representative of the population in the United Kingdom, where primary care physicians manage 97% of cases of atopic eczema (3) .
We identified patients with atopic eczema on the basis of a previously validated algorithm shown to have good positive predictive value for both children and adults in this cohort (90% and 82%, respectively) (4). Because atopic eczema is an episodic disorder that may remit for years, we then calculated the prevalence of active disease requiring a physician visit or prescription during each year of follow-up. We also examined the number and types of prescriptions given to patients and rates of asthma and rhinitis/seasonal allergies by age.
Among 8 604 333 persons aged 0 to 99 years, the cumulative lifetime prevalence of atopic eczema was 9.9% and rates of active disease were highest among children and older adults (Table and Figure) . Patients received a median of 6 prescriptions for atopic eczema per year (interquartile range, 2 to 13 prescriptions), including topical steroids and systemic treatments, and the number of annual prescriptions was sim- ilar across ages. Rates of comorbid atopic disease were highest among adults aged 18 to 74 years. We performed sensitivity analyses to assess for ascertainment and misclassification bias. Because adults may not visit providers as frequently as children and older persons, we tested the effect of basing the definition of active disease only on prescriptions rather than on prescriptions and medical codes from clinic visits. We also examined the effect of excluding persons diagnosed with conditions that may either overlap with or be misdiagnosed as atopic eczema (for example, contact dermatitis, psoriasis, scabies, ichthyosis, erythroderma, photodermatitis, and seborrheic dermatitis) (4) and found results similar to those from our primary analysis (Table) .
Discussion: We have shown that rates of active atopic eczema (as defined by diagnosis and treatment codes applied by physicians) increase with age among adults in primary care, addressing a gap in evidence about the epidemiology of this condition after childhood. The cohort is representative of the U.K. population; however, the true population prevalence of disease activity may be higher than our estimates, because medical records do not capture over-the-counter treatments and providers may not record mild disease. For example, a population-based study of U.S. adults aged 18 to 65 years found a higher 1-year prevalence of self-reported dermatitis overall (10.2%), with the highest rates among persons aged 62 to 85 years (11.4%) (5) .
The presentation and terminology surrounding eczema are heterogeneous, and additional research is needed to understand whether disease pathogenesis is the same across ages. We cannot exclude misclassification bias, which may be higher among adults; however, sensitivity analyses show a similar U-shaped prevalence curve after persons with possible overlapping diagnoses were excluded.
Atopic eczema is known to substantially affect emotional and physical aspects of health-related quality of life but is often undertreated. This circumstance may change as more therapies become available: The U.S. Food and Drug Administration approved 2 new medications for this condition in 2016 and 2017, and more than a dozen additional agents are under development and clinical testing. As new targeted therapies become available, primary care providers will probably play a larger role in managing adults with atopic eczema. Attention should be paid to clinical testing in older adults, who may require special considerations for pharmacology, polypharmacy, and multimorbidity. Local polynomial smoothed plot with shading indicating the 95% CIs generated from cross-sectional calculations of the prevalence of active AE at each age using Stata 15 (StataCorp The telomere length-independent first hit (affecting such genes as DNMT3A, TET2, ASXL1, and JAK2) takes place at the level of hematopoietic stem cells/progenitor cells at the top of the hematopoietic hierarchy. However, the outcomes of the second hit in the expanding clone, primed by the first hit, depend on the patient's telomere length. The wide range of leukocyte telomere lengths across the population (approximately 3 kilobases) (3) suggests vast interindividual variation in the replicative capacity of hematopoietic clones. Before its quantum of cell replications is spent, an expanding hematopoietic clone in a patient with long telomeres would therefore accrue more second-hit mutations than one in a patient with short telomeres; the risk for hematologic cancer thus would be increased in the former patient. In contrast, an expanding hematopoietic clone in a patient with short telomeres would probably exhaust its quantum of replications earlier than one in a patient with long telomeres. This outcome may compromise the bone marrow's ability to generate and dispatch adequately functioning cells engaged in vascular repair and tilt the balance toward proinflammatory cells, thus increasing the risk for atherosclerosis (4) . Such a model is compatible with the role of telomeres in a tradeoff between cancer and atherosclerosis (5) .
Experimental evidence supporting a causal role for CHIP in aging-related diseases is largely based on genetically engineered, short-lived murine models. Most domesticated mice have very long telomeres and robust activity in somatic tissues of telomerase, the enzyme that counters telomere shortening. In contrast, humans-the longest-living terrestrial mammalshave comparatively short telomeres and largely silent telomerase in these tissues. Telomere-mediated replicative senescence therefore may minimally affect mouse biology compared with human biology, underscoring the need to generate knowledge about the telomere length-CHIP nexus and its potential role in hematologic cancer, cardiovascular disease, and death in humans.
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